Patents by Inventor Brian Michael Naiman
Brian Michael Naiman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230201346Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.Type: ApplicationFiled: December 19, 2022Publication date: June 29, 2023Applicant: Boston Pharmaceuticals Inc.Inventors: Catherine ETTINGER, Jodi KARNELL, Melissa DAMSCHRODER, Partha CHOWDHURY, Xiaodong XIAO, Ping TSUI, Reena VARKEY, Stacey DRABIC, Laura CARTER, Ronald HERBST, Qun DU, Brian Michael NAIMAN
-
Patent number: 11529415Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.Type: GrantFiled: February 5, 2020Date of Patent: December 20, 2022Assignee: Boston Pharmaceuticals Inc.Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
-
Publication number: 20200164069Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.Type: ApplicationFiled: February 5, 2020Publication date: May 28, 2020Applicant: Boston Pharmaceuticals Inc.Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
-
Patent number: 10588969Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.Type: GrantFiled: June 11, 2018Date of Patent: March 17, 2020Assignee: Boston Pharmaceuticals, Inc.Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
-
Publication number: 20180318416Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.Type: ApplicationFiled: June 11, 2018Publication date: November 8, 2018Applicant: Boston Pharmaceuticals Inc.Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
-
Patent number: 10022443Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.Type: GrantFiled: April 7, 2015Date of Patent: July 17, 2018Assignee: Boston Pharmaceuticals Inc.Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
-
Publication number: 20170173149Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.Type: ApplicationFiled: April 7, 2015Publication date: June 22, 2017Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman